Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

850 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The NAMPT Inhibitor FK866 Increases Metformin Sensitivity in Pancreatic Cancer Cells.
Parisotto M, Vuong-Robillard N, Kalegari P, Meharwade T, Joumier L, Igelmann S, Bourdeau V, Rowell MC, Pollak M, Malleshaiah M, Schmitzer A, Ferbeyre G. Parisotto M, et al. Among authors: pollak m. Cancers (Basel). 2022 Nov 14;14(22):5597. doi: 10.3390/cancers14225597. Cancers (Basel). 2022. PMID: 36428689 Free PMC article.
Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer.
Mahalingam D, Hanni S, Serritella AV, Fountzilas C, Michalek J, Hernandez B, Sarantopoulos J, Datta P, Romero O, Pillai SMA, Kuhn J, Pollak M, Thompson IM. Mahalingam D, et al. Among authors: pollak m. Oncotarget. 2023 Jun 19;14:622-636. doi: 10.18632/oncotarget.28458. Oncotarget. 2023. PMID: 37335291 Free PMC article. Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 38062296
Correction: Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer.
Mahalingam D, Hanni S, Serritella AV, Fountzilas C, Michalek J, Hernandez B, Sarantopoulos J, Datta P, Romero O, Achutan Pillai SM, Kuhn J, Pollak M, Thompson IM. Mahalingam D, et al. Among authors: pollak m. Oncotarget. 2023 Oct 19;14:890-892. doi: 10.18632/oncotarget.28530. Oncotarget. 2023. PMID: 37861386 Free PMC article. No abstract available.
Exome copy number variant detection, analysis, and classification in a large cohort of families with undiagnosed rare genetic disease.
Lemire G, Sanchis-Juan A, Russell K, Baxter S, Chao KR, Singer-Berk M, Groopman E, Wong I, England E, Goodrich J, Pais L, Austin-Tse C, DiTroia S, O'Heir E, Ganesh VS, Wojcik MH, Evangelista E, Snow H, Osei-Owusu I, Fu J, Singh M, Mostovoy Y, Huang S, Garimella K, Kirkham SL, Neil JE, Shao DD, Walsh CA, Argilli E, Le C, Sherr EH, Gleeson JG, Shril S, Schneider R, Hildebrandt F, Sankaran VG, Madden JA, Genetti CA, Beggs AH, Agrawal PB, Bujakowska KM, Place E, Pierce EA, Donkervoort S, Bönnemann CG, Gallacher L, Stark Z, Tan TY, White SM, Töpf A, Straub V, Fleming MD, Pollak MR, Õunap K, Pajusalu S, Donald KA, Bruwer Z, Ravenscroft G, Laing NG, MacArthur DG, Rehm HL, Talkowski ME, Brand H, O'Donnell-Luria A. Lemire G, et al. Among authors: pollak mr. Am J Hum Genet. 2024 May 2;111(5):863-876. doi: 10.1016/j.ajhg.2024.03.008. Epub 2024 Apr 1. Am J Hum Genet. 2024. PMID: 38565148
Mice with a Pax2 missense variant display impaired glomerular repair.
Cunanan J, Rajyam SS, Sharif B, Udwan K, Rana A, De Gregorio V, Ricardo S, Elia A, Brooks B, Weins A, Pollak M, John R, Barua M. Cunanan J, et al. Among authors: pollak m. Am J Physiol Renal Physiol. 2024 May 1;326(5):F704-F726. doi: 10.1152/ajprenal.00259.2023. Epub 2024 Mar 14. Am J Physiol Renal Physiol. 2024. PMID: 38482556
850 results